

STATE OF WISCONSIN
Pharmacy Examining Board

IN THE MATTER OF RULEMAKING : NOTICE OF TIME PERIOD
PROCEEDINGS BEFORE THE : FOR COMMENTS FOR THE
PHARMACY EXAMINING BOARD : ECONOMIC IMPACT ANALYSIS
:

NOTICE IS HEREBY GIVEN of the time period for public comment on the economic impact of this proposed rule of the Pharmacy Examining Board on Phar 7 and 10 relating to Consumer Disclosures, including how this proposed rule may affect businesses, local government units and individuals. The comments will be considered when the Department of Safety and Professional Services prepares the Economic Impact Analysis pursuant to § 227.137. Written comments may be submitted to:

Nilajah Hardin, Administrative Rules Coordinator
Division of Policy Development
Department of Safety and Professional Services
PO Box 8366
Madison, WI 53708-8935
DSPSAdminRules@wisconsin.gov

The deadline for submitting economic impact comments is February 16, 2023.

PROPOSED ORDER

An order of the Pharmacy Examining Board to **create** Phar 7.15, 10.03 (20), and 10.03 (21), relating to consumer disclosures.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: ss. 15.08 (5) (b), 450.13 (5m), 450.135 (8m), Stats.

Statutory authority: ss. 15.08 (5) (b), 450.02 (3) (a), 450.02 (3) (d), and 450.02 (3) (e), Stats.

Explanation of agency authority:

Section 15.08 (5) (b), Stats. states that “The Board shall promulgate rules for its own guidance and for the guidance of the trade or profession to which it pertains, and define and enforce professional conduct and unethical practices not inconsistent with the law relating to the particular trade or profession.”

Section 450.02 (3) (a), Stats. allows the board to “promulgate rules relating to the manufacture of drugs and the distribution and dispensing of prescription drugs.”

Section 450.02 (3) (d), Stats. says that the board “may promulgate rules necessary for the administration and enforcement of this chapter and ch. 961.”

Section 450.02 (3) (e), Stats. provides that the board “may promulgate rules establishing minimum standards for the practice of pharmacy.”

Related statute or rule: 2021 Wisconsin Act 9

Plain language analysis: The objective of the proposed rule is to revise the Pharmacy administrative code, including but not necessarily limited to chs. Phar 7 and 10, to bring the code into compliance with current statutory provisions as modified by 2021 Wisconsin Act 9.

The Pharmacy Examining Board is required under Act 9 to create and maintain a list of the 100 most commonly prescribed generic drug product equivalents, including the generic and brand name of the drug, which shall be made available to each pharmacy on an annual basis either directly or on the board’s website.

Act 9 created several new requirements for pharmacies as well. A pharmacy must make available to the public information on how to access the list of 100 most commonly prescribed generic drug product equivalents maintained by the Pharmacy Examining Board. Pharmacies also must make available to the public information on how to access the FDA’s list of all currently approved interchangeable biological products. Finally, a pharmacy must maintain disclosures to the public in a conspicuous place near where drugs are dispensed regarding the ability of a pharmacist to substitute a less expensive drug or interchangeable biological product.

Summary of, and comparison with, existing or proposed federal regulation: Federal Regulations part: 21 CFR Subchapter D covers regulations for the FDA on Drugs for Human Use.

Comparison with rules in adjacent states:

Illinois: The Illinois Department of Financial and Professional Regulation (IDFPR) under the State Board of Pharmacy, regulates pharmacists. All consumer disclosures relating to prescription medication and pharmacy benefits management are regulated by the State Department of Insurance. Currently, the Illinois Board of Pharmacy is not responsible, nor regularly provides consumer disclosures regarding generic or prescription medication.

Iowa: Iowa pharmacists are regulated by the Board of Pharmacists. All consumer disclosures relating to prescription medication and pharmacy benefits management are regulated by the State Department of Insurance. Currently, the Iowa Board of Pharmacists is not responsible, nor regularly provides consumer disclosures regarding generic or prescription medication.

Michigan: The Michigan Department of Licensing and Regulatory Affairs (MDLRA) regulates pharmacists under the authority of the Michigan Board of Pharmacy. All consumer disclosures relating to prescription medication and pharmacy benefits management are regulated by the State Department of Insurance. Currently, the Michigan Board of Pharmacy is not responsible, nor regularly provides consumer disclosures regarding generic or prescription medication.

Minnesota: In Minnesota, pharmacists are regulated by the Minnesota Department of Health, with input from the Minnesota Board of Pharmacy. All consumer disclosures relating to prescription medication and pharmacy benefits management are regulated by the State Department of Insurance. Currently, the Minnesota Board of Pharmacy is not responsible, nor regularly provides consumer disclosures regarding generic or prescription medication.

Summary of factual data and analytical methodologies:

The proposed rules were developed by reviewing the current federal food and drug-approved interchangeable biological products; technical information provided by the American Pharmacists Association (APhA), and 2021 Wisconsin Act 9, relating to pharmacy benefit managers, prescription drug benefits, and granting rule-making authority.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:

The rule will be posted for 14 days on the Department of Safety and Professional Services website to solicit economic impact comments, including how the proposed rules may affect businesses, local municipalities, and private citizens.

Fiscal Estimate and Economic Impact Analysis:

The Fiscal Estimate and Economic Impact Analysis will be attached upon completion.

Effect on small business:

These rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator, Dan Hereth, may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

Agency contact person:

Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, P.O. Box 8366, Madison, Wisconsin 53708-8366; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

Place where comments are to be submitted and deadline for submission:

Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, P.O. Box 8366, Madison, Wisconsin 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received on or before the public hearing, held on a date to be determined, to be included in the record of rule-making proceedings.

TEXT OF RULE

SECTION 1. Phar 7.15 is created to read:

Phar 7.15 Consumer Disclosures.

(1) Each pharmacy shall post in a prominent place and maintain the consumer disclosures required in ss. 450.13 (5m) and 450.135 (8m), Stats.

(2) The Board shall maintain a link to the 100 most commonly prescribed generic drug product equivalents on the Department website as required in s. 450.13 (5m) (b), Stats.

Note: Copies of the required consumer disclosures are located on the Department of Safety and Professional Service’s website: <https://dsps.wi.gov>

(3) Pursuant to s. 450.13 (5m) (c), Stats., each pharmacy shall maintain and make available to the public a list of the drugs from the list in Phar 7.15 (2) that are available for purchase at that pharmacy. The list shall be updated monthly, with all of the following information included:

- (a) brand name
- (b) generic equivalent drugs and biological products
- (c) interchangeable biological products
- (d) retail price

(4) The list required under Phar 7.15 (3) may differ depending on whether the drugs on the list from Phar 7.15 (2) are available for purchase at a specific pharmacy.

SECTION 2. Phar 10.03 (20) and (21) are created to read:

Phar 10.03 (20) Violating or attempting to violate any provision or term of ch. 450, Stats., or of any valid rule of the board.

Phar 10.03 (21) Failure to comply with ss 450.13 (5m) or 450.135 (8m), Stats.

SECTION 3. EFFECTIVE DATE. the rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)
